We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer’s Hospira Facility in India Hit With Lengthy 483
Pfizer’s Hospira Facility in India Hit With Lengthy 483
The FDA cited Pfizer’s Hospira manufacturing facility in Sriperumbudur, Tamil Nadu for a slew of repeat deficiencies, including falsifying data, in a Form 483 flagged as Official Action Indicated – indicating that the agency is planning further enforcement action against the company within six months.